HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HIV/AIDS, Cancer Cure Supplement Claims Targeted In Six FTC Actions

This article was originally published in The Tan Sheet

Executive Summary

Western Dietary Products will preliminarily halt Internet marketing claims that its black walnut, wormwood and clove tinctures treat and cure diseases such as cancer, diabetes and HIV/AIDS, the Federal Trade Commission says.

You may also be interested in...



FTC

Western Dietary Products prohibited from misrepresenting use of firm's products in treating cancer, making surgery or chemotherapy unnecessary, according to stipulated final judgment filed in Seattle federal court, commission announces Dec. 28. Company, which marketed "herbal cure packages" and Zapper Electrical Unit, stipulated to entry of a preliminary injunction in June after FTC sued firm for allegedly making false, deceptive and unsubstantiated health claims for supplements, devices over the Internet (1"The Tan Sheet" June 18, 2001, p. 12)...

FDA, FTC, 30 State AGs Join Forces To Combat Fraudulent Anthrax Products

The Federal Trade Commission is renewing efforts to track down colloidal silver supplements sold online under a federal and state multi-agency campaign against fraudulent products indicated for anthrax

Comfrey Presents "Serious Health Hazard," ONPLDS Tells Industry

Marketers of comfrey-containing dietary supplements should recall all such products or face direct enforcement action, FDA asserts in a July 6 letter sent to eight trade groups.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel